Evidence map›Paper›PMID 24906497›Full record

ArticlePflugers Archiv : European journal of physiology2015

Sensitisation of TRPV4 by PAR2 is independent of intracellular calcium signalling and can be mediated by the biased agonist neutrophil elastase.

Silvia Sostegni, Alexei Diakov, Peter McIntyre, Nigel Bunnett, Christoph Korbmacher, Silke Haerteis

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Pflugers Archiv : European journal of physiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.0field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Cathepsin S Evokes PARCancers · 2021
    Article
  6. Article
  7. Visceral pain from colon and rectum: the mechanotransduction and biomechanics.Journal of neural transmission (Vienna, Austria : 1996) · 2020
    Review
  8. Transient receptor potential cation channel subfamily V and breast cancer.Laboratory investigation; a journal of technical methods and pathology · 2020
    Review
  9. Review
  10. Article
  11. Article
  12. TRPV4 as a therapeutic target for joint diseases.Naunyn-Schmiedeberg's archives of pharmacology · 2015
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Silvia SostegniInstitut für Zelluläre und Molekulare Physiologie, Friedrich-Alexander-Universität Erlangen-Nürnberg, Waldstr. 6, 91054, Erlangen, Germany.
Alexei Diakov
Peter McIntyre
Nigel Bunnett
Christoph Korbmacher
Silke Haerteis
Friedrich-Alexander-Universität Erlangen-Nürnberg · DERMIT University · AUUniversity of Melbourne · AU

Funding

Endosomal Platforms for Signaling PainR01NS102722 · NINDS · NEW YORK UNIVERSITY · PI NIGEL W BUNNETT, Brian L Schmidt · 2017 to 2026
$3.4M
NINDS NIH HHS R01 NS102722
6 · The paper itself

Abstract

Proteolytic activation of protease-activated receptor 2 (PAR2) may represent a major mechanism of regulating the transient receptor potential vanilloid 4 (TRPV4) non-selective cation channel in pathophysiological conditions associated with protease activation (e.g. during inflammation). To provide electrophysiological evidence for PAR2-mediated TRPV4 regulation, we characterised the properties of human TRPV4 heterologously expressed in Xenopus laevis oocytes in the presence and absence of co-expressed human PAR2. In outside-out patches from TRPV4 expressing oocytes, we detected single-channel activity typical for TRPV4 with a single-channel conductance of about 100 pS for outward and 55 pS for inward currents. The synthetic TRPV4 activator GSK1016790A stimulated TRPV4 mainly by converting previously silent channels into active channels with an open probability of nearly one. In oocytes co-expressing TRPV4 and PAR2, PAR2 activation by trypsin or by specific PAR2 agonist SLIGRL-NH2 potentiated the GSK1016790A-stimulated TRPV4 whole-cell currents several fold, indicative of channel sensitisation. Pre-incubation of oocytes with the calcium chelator 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA)-AM did not reduce the stimulatory effect of PAR2 activation on TRPV4, which indicates that the effect is independent of intracellular calcium signalling. Neutrophil elastase, a biased agonist of PAR2 that does not induce intracellular calcium signalling, also caused a PAR2-dependent sensitisation of TRPV4. The Rho-kinase inhibitor Y27362 abolished elastase-stimulated sensitisation of TRPV4, which indicates that Rho-kinase signalling plays a critical role in PAR2-mediated TRPV4 sensitisation by the biased agonist neutrophil elastase. During acute inflammation, neutrophil elastase may sensitise TRPV4 by a mechanism involving biased agonism of PAR2 and activation of Rho-kinase.

Indexed as

Calcium SignalingAnimalsHumansLeucineLeukocyte ElastaseOligopeptidesProteolysisReceptor, PAR-2rho-Associated KinasesSulfonamidesTRPV Cation ChannelsTrypsinXenopusLeucineLeukocyte ElastaseN-(1-((4-(2-(((2,4-dichlorophenyl)sulfonyl)amino)-3-hydroxypropanoyl)-1-piperazinyl)carbonyl)-3-methylbutyl)-1-benzothiophene-2-carboxamideOligopeptidesReceptor, PAR-2rho-Associated Kinasesseryl-leucyl-isoleucyl-glycyl--arginyl-leucinamideSulfonamidesTRPV4 protein, humanTRPV Cation ChannelsTrypsin

Identifiers

PMID24906497
PMCPMC11450633
OpenAlexW2164401496

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.